Skip to content

Ranked by human evidence

Best Peptides for Energy, Ranked by Human Evidence

L-carnitine injection has the strongest human evidence for energy, but for its approved use in diagnosed carnitine deficiency, not for energy in healthy people. SS-31 has 16 randomised trials, all in people with diagnosed diseases, and for NAD+ injections, MOTS-c and the growth-hormone peptides I found no trial that measured energy.

Growth-hormone peptides like CJC-1295 and Ipamorelin can raise GH and IGF-1 in studies, but human evidence for energy and sleep benefits is thin, and they are research-use-only, not approved for human use.

Related: Peptides for sleep · Peptides for mitochondrial dysfunction · NAD+ injections vs peptides

Peptides for energy, ranked by human evidence

The order is the strength of human evidence, strongest first: strong, moderate, limited, animal or lab only, then none. Ties keep the site's usual compound order. A higher rank means more and better human studies, not that a compound works for energy, so check what each study measured.

Peptides for energy compared: evidence level, US legal status and what human studies measured
RankCompoundEvidenceUS statusMeasured in humansGuide
1L-Carnitine (injection)Strong human evidenceFDA-approved · prescription onlyIts approved use in diagnosed carnitine deficiency, including dialysis patients; for weight, a meta-analysis of 37 trials of oral L-carnitine found a modest drop.Read
2SS-31Moderate human evidenceFDA-approved · prescription onlyMuscle strength in Barth syndrome (accelerated approval); its largest trial, in mitochondrial myopathy, missed its primary endpoints.Read
3SermorelinLimited human dataUnapproved drugGrowth in children with growth hormone deficiency; an IGF-1 blood marker in hypogonadal men.Read
4DSIPLimited human dataResearch use onlySleep in chronic insomnia in one randomised trial, published in 1992; its other trials covered hormone measures and anaesthesia.Read
5CJC-1295Limited human dataResearch use onlyGrowth hormone and IGF-I levels in healthy adults (DAC form only); no muscle, strength or fat outcomes.Read
6IpamorelinLimited human dataResearch use onlyHow the body clears it in healthy men, and a Phase 2 programme in postoperative ileus that stopped for insufficient efficacy.Read
7NAD+ (injection)Limited human dataUnapproved drugHow the body clears an IV dose, and tolerability; no energy, aging or cognition outcomes.Read
8AICARLimited human dataUnapproved drugDeath, stroke and heart damage in over 3,000 bypass patients, with no benefit; never tested for endurance in people.Read
9MOTS-cAnimal / lab onlyResearch use onlyOnly the body's own MOTS-c levels, for example after exercise; no completed trial has given it to people.Read
10SLU-PP-332Animal / lab onlyUnapproved drugNone: I located no trial, case report or human dosing study.Read
  1. Prescription / GLP-1FDA-approved · prescription only

    1. L-Carnitine (injection)

    Strong human evidence

    Measured in humans: Its approved use in diagnosed carnitine deficiency, including dialysis patients; for weight, a meta-analysis of 37 trials of oral L-carnitine found a modest drop.

    Why this rating

    FDA approved CARNITOR injection based on trials in its approved population: patients with an inborn error of metabolism causing secondary carnitine deficiency, and dialysis patients with carnitine deficiency, including a dose-ranging study in end-stage renal disease patients on hemodialysis. That approval and evidence base is specific to diagnosed deficiency, not to fat loss in someone without it. For the separate off-label weight-loss use, the best evidence I verified is a meta-analysis of 37 randomized trials of oral (not injectable) L-carnitine, finding a modest reduction in body weight and fat mass in adults, though only the body-weight effect held in the high-quality trials and the dose-response link was for body weight alone - real human RCT evidence, but for a different route and a different population than the injection sold in weight-loss clinics.

  2. Research peptidesFDA-approved · prescription only

    2. SS-31

    Moderate human evidence

    Measured in humans: Muscle strength in Barth syndrome (accelerated approval); its largest trial, in mitochondrial myopathy, missed its primary endpoints.

    Why this rating

    Sixteen randomised trials, all in diagnosed patients: primary mitochondrial myopathy through dose-escalation and crossover designs to a large controlled study, plus Barth syndrome and a topical ophthalmic formulation. The lead trial in primary mitochondrial myopathy did not meet its primary endpoints. In Barth syndrome, FDA granted accelerated approval in September 2025 on an improvement in knee extensor muscle strength, an intermediate endpoint, with continued approval contingent on a confirmatory trial. No trial has studied healthy adults.

  3. Prescription / GLP-1Unapproved drug

    3. Sermorelin

    Limited human data

    Measured in humans: Growth in children with growth hormone deficiency; an IGF-1 blood marker in hypogonadal men.

    Why this rating

    Randomised trials exist but sit in paediatric growth hormone deficiency, and the review reporting the treatment regimen hedges it as limited data with the effect on final adult height yet to be determined. The nearest adult evidence is an IGF-1 biomarker result in hypogonadal men. No randomised trial in healthy adults for the marketed outcomes was located.

  4. Research peptidesResearch use only

    4. DSIP

    Limited human data

    Measured in humans: Sleep in chronic insomnia in one randomised trial, published in 1992; its other trials covered hormone measures and anaesthesia.

    Why this rating

    Six records tagged as randomised trials across a literature of 519 papers, and only one concerns the marketed use - DSIP in chronic insomniacs, published in 1992. The others cover endocrine measures, a glucocorticoid and REM sleep study where DSIP sits in the design, and anaesthesia depth monitoring.

  5. Research peptidesResearch use only

    5. CJC-1295

    Limited human data

    Measured in humans: Growth hormone and IGF-I levels in healthy adults (DAC form only); no muscle, strength or fat outcomes.

    Why this rating

    Human pharmacokinetic data exists for the DAC form only, from two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, reported in one 2006 paper. Those are surrogate hormone measures, not clinical outcomes, and development was discontinued at Phase 2. The without-DAC form (mod GRF 1-29) has no published human pharmacokinetic study I could locate. One entry, two very different evidence bases.

  6. Research peptidesResearch use only

    6. Ipamorelin

    Limited human data

    Measured in humans: How the body clears it in healthy men, and a Phase 2 programme in postoperative ileus that stopped for insufficient efficacy.

    Why this rating

    The selectivity finding it is famous for is in vitro and animal data only - rat pituitary cells, anaesthetised rats, conscious swine. Human data is limited to a pharmacokinetic study in healthy men (terminal half-life 2 hours) and a Phase 2 program in postoperative ileus that was discontinued for insufficient efficacy. So there is human data - and what it showed was a failure to demonstrate benefit.

  7. Research peptidesUnapproved drug

    7. NAD+ (injection)

    Limited human data

    Measured in humans: How the body clears an IV dose, and tolerability; no energy, aging or cognition outcomes.

    Why this rating

    Two published human studies of IV NAD+ are in my verified registry: a 2019 pharmacokinetic pilot tracking plasma and urine NAD+ metabolites over a 6-hour infusion, and a 2026 retrospective clinic-record comparison of IV NAD+ against IV nicotinamide riboside measuring tolerability and short-term safety markers. Both are pharmacokinetic or tolerability studies, not controlled efficacy trials - neither measured the energy, anti-aging, cognitive or addiction-recovery outcomes marketed to consumers, so those claims remain unverified against my registry.

  8. Research peptidesUnapproved drug

    8. AICAR

    Limited human data

    Measured in humans: Death, stroke and heart damage in over 3,000 bypass patients, with no benefit; never tested for endurance in people.

    Why this rating

    This is one of the few grey-market compounds with real human randomised-trial data - it just was not designed to test what buyers are told AICAR does. A large, multicentre, randomised, placebo-controlled human trial (the RED-CABG trial, over 3,000 patients undergoing bypass surgery) tested acadesine and found it did not reduce the combined rate of death, nonfatal stroke or severe cardiac dysfunction, leading the trial to stop early on a futility analysis. That is real human trial-level evidence, and it does not support the compound. Separately, the endurance and fat-loss reputation this compound is actually marketed for traces to one mouse study, using doses roughly 5,000-10,000 times higher per kilogram than any human dose ever given, that has never been replicated in a human endurance trial of any kind.

  9. Research peptidesResearch use only

    9. MOTS-c

    Animal / lab only

    Measured in humans: Only the body's own MOTS-c levels, for example after exercise; no completed trial has given it to people.

    Why this rating

    The four human records tagged as randomised trials all measure endogenous MOTS-c responding to exercise, metformin or heat stress. None administers MOTS-c to anyone. One Phase 2 trial giving subcutaneous MOTS-c to adults with prediabetes is recruiting, with primary completion due February 2027, and has reported nothing.

  10. Research peptidesUnapproved drug

    10. SLU-PP-332

    Animal / lab only

    Measured in humans: None: I located no trial, case report or human dosing study.

    Why this rating

    Every finding I verified for SLU-PP-332 is from mouse studies, published in peer-reviewed journals: repeated ERR agonist dosing produced exercise-mimicking muscle-fibre and metabolic changes, and enhanced treadmill endurance, in mice. I located no published human trial, case report or clinical dosing study of any kind. Vendor pages selling it as a research chemical describe human clinical activity as "emerging but early," not established, which is consistent with what I found.

Common questions about peptides for energy

Which peptides help with energy?

I found none with trial evidence for more energy in healthy adults. The strongest human evidence on this page belongs to L-carnitine injection, approved for diagnosed carnitine deficiency, and SS-31, approved for muscle strength in Barth syndrome. Both were tested in patients with a diagnosed condition, not in people who simply feel tired.

Is there a peptide for fatigue?

Not one with evidence in everyday fatigue. NAD+ drips are marketed for it, but the 2 published human studies I verified measured how the body clears a dose and how well it is tolerated. SS-31's largest trial, in primary mitochondrial myopathy, did not meet its primary endpoints.

Do growth-hormone peptides improve energy?

They can raise growth hormone and IGF-1 in studies, but human evidence for energy or sleep benefits is thin. CJC-1295's trials measured hormone levels, ipamorelin's Phase 2 programme was in postoperative ileus, and sermorelin's controlled trials were in children with growth hormone deficiency.

Does AICAR improve endurance in humans?

I found no human endurance trial of it. Its reputation comes from one mouse study, at doses roughly 5,000 to 10,000 times higher per kilogram than any human dose. Given by drip as acadesine to over 3,000 heart-surgery patients, it did not reduce death, stroke or heart damage.

Is DSIP good for sleep?

Its name comes from an early proposed role, not a proven one. Of 6 randomised trials in its literature, only 1, published in 1992, tested it in people with chronic insomnia, and research on it has been winding down since the 1980s.

Guides on peptides for energy

Best peptides for other goals